patient subgroup...
Age < 65y (younger) Age > 65y Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), Immune checkpoint association versus pembrolizumab alone, meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 1.08 [0.85, 1.37]< 1 0% 1 study (1/-) 26.4 % NA not evaluable crucial - progression or deaths (PFS) 1.06 [0.86, 1.30]< 1 0% 1 study (1/-) 29.0 % NA not evaluable important - objective responses (ORR) 1.00 [0.72, 1.39]> 1 0% 1 study (1/-) 50.0 % NA not evaluable non important - AE (grade 3-4) endpoints 00 Anaemia AE (grade 3-4) 1.14 [0.41, 3.20]< 1 0% 1 study (1/-) 40.0 % NA not evaluable non important - Arthralgia AE (grade 3-4) 2.01 [0.36, 11.05]< 1 0% 1 study (1/-) 21.3 % NA not evaluable non important - Asthenia AE (grade 3-4) 0.25 [0.03, 2.22]< 1 0% 1 study (1/-) 89.3 % NA not evaluable non important - Back pain AE (grade 3-4) 0.50 [0.04, 5.51]< 1 0% 1 study (1/-) 71.4 % NA not evaluable non important - Constipation AE (grade 3-4) 1.00 [0.14, 7.12]< 1 0% 1 study (1/-) 50.1 % NA not evaluable non important - Cough AE (grade 3-4) 0.50 [0.02, 14.89]< 1 0% 1 study (1/-) 65.4 % NA not evaluable non important - Decreased appetite AE (grade 3-4) 6.03 [0.30, 120.98]< 1 0% 1 study (1/-) 12.3 % NA not evaluable non important - Diarrhoea AE (grade 3-4) 10.29 [1.31, 80.96]< 1 0% 1 study (1/-) 1.4 % NA not evaluable non important - Dyspnoea AE (grade 3-4) 0.87 [0.31, 2.43]< 1 0% 1 study (1/-) 60.6 % NA not evaluable non important - Fatigue AE (grade 3-4) 1.51 [0.42, 5.39]< 1 0% 1 study (1/-) 26.5 % NA not evaluable non important - Hypothyroidism AE (grade 3-4) 1.00 [0.06, 16.01]< 1 0% 1 study (1/-) 50.1 % NA not evaluable non important - Increase AST AE (grade 3-4) 2.52 [0.48, 13.09]< 1 0% 1 study (1/-) 13.7 % NA not evaluable non important - Increased ALT AE (grade 3-4) 2.28 [0.69, 7.50]< 1 0% 1 study (1/-) 8.7 % NA not evaluable non important - Nausea AE (grade 3-4) 4.01 [0.18, 89.26]< 1 0% 1 study (1/-) 19.3 % NA not evaluable non important - Pneumonia AE (grade 3-4) 1.36 [0.72, 2.56]< 1 0% 1 study (1/-) 17.2 % NA not evaluable non important - Pneumonitis AE (grade 3-4) 2.21 [0.83, 5.91]< 1 0% 1 study (1/-) 5.6 % NA not evaluable non important - Pruritus AE (grade 3-4) 0.50 [0.04, 5.51]< 1 0% 1 study (1/-) 71.4 % NA not evaluable non important - Pyrexia AE (grade 3-4) 6.03 [0.30, 120.98]< 1 0% 1 study (1/-) 12.3 % NA not evaluable non important - Rash AE (grade 3-4) 16.38 [0.94, 286.59]< 1 0% 1 study (1/-) 2.9 % NA not evaluable non important - Vomiting AE (grade 3-4) 4.03 [0.45, 36.27]< 1 0% 1 study (1/-) 10.8 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.